Literature DB >> 21159897

Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial.

Tina Thethi, Mohan Rajapurkar, Patrick Walker, Roberta McDuffie, David C Goff, Jeffrey Probstfield, C Lillian Yau, Sudhir Shah, Uwe Christians, John Buse, Vivian Fonseca.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21159897     DOI： 10.1373/clinchem.2010.155887

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  4 in total

Review 1.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

2.  Iron and diabetes revisited.

Authors:  Sudhir V Shah; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2011-07       Impact factor: 19.112

3.  BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease.

Authors:  Saideh Fakharzadeh; Hassan Argani; Simin Dadashzadeh; Somayeh Kalanaky; Peyman Mohammadi Torbati; Mohammad Hassan Nazaran; Abbas Basiri
Journal:  Diabetes Metab Syndr Obes       Date:  2020-04-17       Impact factor: 3.168

Review 4.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.